Update on phase III LEAP-001 trial evaluating Keytruda (pembrolizumab) + Lenvima (lenvatinib) as first-line treatment for advanced or recurrent endometrial carcinoma – Merck Inc + Eisai
Merck Inc., known as MSD outside of the United States and Canada, and Eisai announced that the Phase III LEAP-001 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, plus Lenvima,… read more.
